Yoda Therapeutics has successfully dosed its first patient in the Phase 2 trial of YA-101 for multiple system atrophy, a significant advancement for this rare disease.

多系統萎縮症治療を目指すYA-101の第2相試験が日本でも始まり、患者への希望が広がります。Yoda Therapeuticsの進捗に注目です。